Why the study?
Does intravenous 7E3-F(ab')2 inhibit platelet aggregation in a human neomort model?
Does intravenous 7E3-F(ab')2 inhibit platelet aggregation in a human neomort model?
Answers are grounded in this paper and cite their sources.
The 7E3-F(ab')2 monoclonal antibody fragment demonstrates potent, immediate-acting inhibition of platelet aggregation in a human neomort model, providing early evidence for its potential as an antithrombotic agent.
The F(ab')2 fragment of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor (7E3) is a potent inhibitor of both in-vitro platelet aggregation and in-vivo platelet thrombus formation in animal studies. As a first step in assessing the potential of 7E3-F(ab')2 as an antithrombotic agent for use in humans, we administered 7E3-F(ab')2 intravenously at increasing doses to a person who had just died and was being maintained on a respirator (neomort). At 0.1 and at 0.2 mg/kg body weight, 74% and 92% of the glycoprotein IIb/IIIa receptors were blocked, respectively; adenosine-diphosphate-induced platelet aggregation was inhibited by 84% and 100% at these same doses. Platelet glycoprotein Ib function remained intact, even at 0.6 mg/kg. Acute hemodynamic or hemorrhagic toxicity was not noted. This antibody fragment, a potent, immediate-acting inhibitor of platelet aggregation, may be of benefit in vaso-occlusive and thromboembolic disorders.
No takes yet. Share an insight, caveat, or question.
Barry S. Coller (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: